Cell Culture Scale-Up
When culturing stem cells, "scale-up" can take on various meanings depending on your goals. Whether you want to increase the quantity or yield of your chosen cell type(s), move from traditional two-dimensional (2D) culture systems to three-dimensional (3D) platforms, or transition to large-scale clinical manufacturing, º£½ÇÆƽâ°æ Technologies can support you with tools, expertise, and guidance tailored to every aspect of scale-up.
Browse the resources below for insights on scaling up human pluripotent stem cells (hPSCs), immune cells, hematopoietic stem and progenitor cells (HSPCs), and other specialized cell types. Topics include maintaining characteristics like pluripotency and differentiation potential, meeting compliance regulations, optimizing cultures to achieve high yields, and adopting systems to mimic in vivo conditions for disease modeling, drug discovery, and therapeutic development.
On-Demand Ancillary Materials Course
In this self-paced, virtual course, you will learn how ancillary materials influence the safety, consistency, and scalability of cell and gene therapy manufacturing. Understanding these impacts is essential to successfully scaling up production while maintaining product quality and regulatory compliance.
Register Now >-
Differentiation of Human Pluripotent Stem Cells to Immune Cells for Cell Therapy DevelopmentIn this webinar, Diana Golubeva, Scientist in the Immunology group at º£½ÇÆƽâ°æ Technologies, presents a robust, scalable platform for differentiating human pluripotent stem cells (hPSCs) into functional immune cells for allogeneic cell therapy development. By integrating TeSRâ„¢-AOF 3D for xeno-free suspension culture and STEMdiffâ„¢ Hematopoietic-EB reagents, the protocol enables efficient, high-yield generation of CD34⺠hematopoietic stem and progenitor cells (HSPCs). These HSPCs serve as a foundation for downstream differentiation into lymphoid lineages—including natural killer (NK), T, and B cells—using STEMdiffâ„¢ and StemSpanâ„¢ kits, all optimized for feeder-free workflows and scalable bioreactor formats.<br><br>As a supporter of, and participant in, ISSCR’s 2025 Annual Meeting, we share with you our presentation at ISSCR 2025. This presentation does not represent an endorsement from or support of the ISSCR. -
Hematopoietic Stem Cell Fitness and Function During Sickle Cell DiseaseChronic insults, such as inflammation and replicative stress, impair and exhaust blood-sustaining hematopoietic stem cells (HSCs), leading to dysfunction and selection for leukemia-associated mutations. Dr. McKinney-Freeman’s laboratory is currently studying how sickle cell disease (SCD), an inherited hemolytic anemia with a large inflammatory component and increased hematopoietic demand, compromises the fidelity and function of hematopoietic stem cells (HSCs) in both mice and individuals with SCD. Mounting evidence indicates that SCD patients may experience enhanced rates of clonal hematopoiesis, as well as MDS (myelodysplastic syndrome) and AML (acute myeloid leukemia), in general, and following allogeneic HSC transplantation or autologous HSC gene therapy. Considering that these are the only curative therapies for SCD, it is important to better understand and prevent SCD-induced insults to HSCs and their microenvironment. <br><br> In this webinar, Dr. McKinney-Freeman from St. Jude Children’s Research Hospital describes, in detail, what her laboratory has learned about how SCD affects HSCs. Additionally, Dr. McKinney-Freeman is joined by Dr. Eric Norris, Account Executive, Cell Culture, º£½ÇÆƽâ°æ Technologies in the Q&A session.
